06/01/2007
Federal Register Notice: FDA has determined the regulatory review period for GEM 21S Growth Factor Enhanced Matrix is 1,361 days f...05/25/2007
Federal Register Notice: FDA has determined the regulatory review period for Genzyme Corp.’s Myozyme is 1,225 days for exten...05/25/2007
Federal Register Notice: FDA has determined the regulatory review period for Ortho Biotech’s Prezista is 1,253 days for exte...05/25/2007
Federal Register Notice: FDA will consider comments submitted through 5/29, for a draft guidance for industry entitled Complementa...05/25/2007
Federal Register Notice: FDA has determined the regulatory review period for Bristol-Myers Squibb’s Sprycel, NDAs 21- 986 an...05/25/2007
Federal Register Notice: FDA has determined the regulatory review period for Medtronic Inc.’s KDR 401 and 403 pacemakers is ...05/22/2007
Federal Register Notice: FDA has determined the regulatory review period for Shire’s Fosrenol is 2,449 days for the extendin...05/21/2007
Federal Register Notice: FDA’s Science Board will meet 6/14, from 8 a.m. to 4 p.m. at the Holiday Inn Gaithersburg, 2 Montgo...